This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-20a-5p | ABHD2 | 0.85 | 0 | -1.2 | 0 | miRNATAP | -0.28 | 0 | NA | |
2 | hsa-miR-20a-5p | ABHD5 | 0.85 | 0 | -0.6 | 0 | MirTarget | -0.12 | 1.0E-5 | NA | |
3 | hsa-miR-20a-5p | ACER3 | 0.85 | 0 | 0.02 | 0.84604 | mirMAP | -0.12 | 2.0E-5 | NA | |
4 | hsa-miR-20a-5p | ACOX1 | 0.85 | 0 | -1.16 | 0 | mirMAP | -0.15 | 0.00046 | NA | |
5 | hsa-miR-20a-5p | ACSL6 | 0.85 | 0 | 0.39 | 0.26458 | mirMAP | -0.21 | 0.03388 | NA | |
6 | hsa-miR-20a-5p | ACTR3C | 0.85 | 0 | -0.99 | 0 | mirMAP | -0.21 | 1.0E-5 | NA | |
7 | hsa-miR-20a-5p | ADAM9 | 0.85 | 0 | 0.47 | 0.00581 | miRNATAP | -0.24 | 0 | NA | |
8 | hsa-miR-20a-5p | ADAMTS5 | 0.85 | 0 | -0.16 | 0.36499 | miRNATAP | -0.16 | 0.00122 | NA | |
9 | hsa-miR-20a-5p | ADARB1 | 0.85 | 0 | -0.13 | 0.22208 | MirTarget | -0.11 | 0.00024 | NA | |
10 | hsa-miR-20a-5p | ADRA2A | 0.85 | 0 | -0.76 | 0.02558 | miRNATAP | -0.4 | 2.0E-5 | NA | |
11 | hsa-miR-20a-5p | AFF4 | 0.85 | 0 | -0.64 | 0 | miRNATAP | -0.13 | 0 | NA | |
12 | hsa-miR-20a-5p | AHRR | 0.85 | 0 | 0.37 | 0.09373 | MirTarget | -0.13 | 0.04288 | NA | |
13 | hsa-miR-20a-5p | AKAP13 | 0.85 | 0 | -0.32 | 0.00142 | MirTarget; mirMAP; miRNATAP | -0.12 | 1.0E-5 | NA | |
14 | hsa-miR-20a-5p | AKT3 | 0.85 | 0 | -0.66 | 0.00047 | miRNATAP | -0.29 | 0 | NA | |
15 | hsa-miR-20a-5p | AKTIP | 0.85 | 0 | -0.37 | 0.00054 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
16 | hsa-miR-20a-5p | ALDH1A3 | 0.85 | 0 | -2.13 | 0 | mirMAP | -0.58 | 0 | NA | |
17 | hsa-miR-20a-5p | ALDH3A2 | 0.85 | 0 | -0.55 | 0.00022 | mirMAP | -0.1 | 0.01404 | NA | |
18 | hsa-miR-20a-5p | ANKIB1 | 0.85 | 0 | 0.07 | 0.50551 | miRNATAP | -0.11 | 6.0E-5 | NA | |
19 | hsa-miR-20a-5p | ANKRD29 | 0.85 | 0 | 1.13 | 4.0E-5 | MirTarget | -0.34 | 1.0E-5 | NA | |
20 | hsa-miR-20a-5p | ANKRD50 | 0.85 | 0 | -0.25 | 0.04433 | MirTarget; miRNATAP | -0.2 | 0 | NA | |
21 | hsa-miR-20a-5p | ANO6 | 0.85 | 0 | -0.29 | 0.00464 | MirTarget | -0.11 | 0.00024 | NA | |
22 | hsa-miR-20a-5p | APBB2 | 0.85 | 0 | -0.24 | 0.03085 | MirTarget; miRNATAP | -0.19 | 0 | NA | |
23 | hsa-miR-20a-5p | APCDD1 | 0.85 | 0 | -1.3 | 0.00043 | MirTarget | -0.34 | 0.00121 | NA | |
24 | hsa-miR-20a-5p | AR | 0.85 | 0 | -2.66 | 0 | mirMAP | -0.73 | 0 | NA | |
25 | hsa-miR-20a-5p | ARAP2 | 0.85 | 0 | -1.13 | 0 | MirTarget | -0.21 | 1.0E-5 | NA | |
26 | hsa-miR-20a-5p | ARHGAP23 | 0.85 | 0 | -0.14 | 0.32985 | mirMAP | -0.18 | 2.0E-5 | NA | |
27 | hsa-miR-20a-5p | ARHGAP24 | 0.85 | 0 | -0.99 | 0 | MirTarget | -0.24 | 0 | NA | |
28 | hsa-miR-20a-5p | ARL10 | 0.85 | 0 | -0.42 | 0.01556 | mirMAP | -0.1 | 0.03875 | NA | |
29 | hsa-miR-20a-5p | ARL13B | 0.85 | 0 | -0.32 | 0.01196 | MirTarget | -0.11 | 0.00134 | NA | |
30 | hsa-miR-20a-5p | ARL4C | 0.85 | 0 | -0.83 | 1.0E-5 | MirTarget; miRNATAP | -0.11 | 0.04188 | NA | |
31 | hsa-miR-20a-5p | ARSD | 0.85 | 0 | -1.16 | 0 | mirMAP | -0.33 | 0 | NA | |
32 | hsa-miR-20a-5p | ASPA | 0.85 | 0 | -2.88 | 0 | mirMAP | -0.23 | 0.00712 | NA | |
33 | hsa-miR-20a-5p | ATE1 | 0.85 | 0 | -0.6 | 0.0009 | MirTarget | -0.11 | 0.02845 | NA | |
34 | hsa-miR-20a-5p | ATL3 | 0.85 | 0 | 0.13 | 0.25255 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.2 | 0 | NA | |
35 | hsa-miR-20a-5p | ATP1A2 | 0.85 | 0 | 0.51 | 0.11121 | MirTarget; miRNATAP | -0.32 | 0.00041 | NA | |
36 | hsa-miR-20a-5p | ATRX | 0.85 | 0 | -0.07 | 0.48759 | mirMAP | -0.13 | 0 | NA | |
37 | hsa-miR-20a-5p | ATXN1L | 0.85 | 0 | 0.09 | 0.38956 | miRNATAP | -0.13 | 0 | NA | |
38 | hsa-miR-20a-5p | BBX | 0.85 | 0 | -0.07 | 0.54321 | MirTarget; miRNATAP | -0.18 | 0 | NA | |
39 | hsa-miR-20a-5p | BCL2 | 0.85 | 0 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | NA | |
40 | hsa-miR-20a-5p | BHLHE41 | 0.85 | 0 | -0.4 | 0.15906 | miRNATAP | -0.43 | 0 | NA | |
41 | hsa-miR-20a-5p | BMPR2 | 0.85 | 0 | -0.74 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.24 | 0 | NA | |
42 | hsa-miR-20a-5p | BNC2 | 0.85 | 0 | -0.39 | 0.08973 | miRNATAP | -0.36 | 0 | NA | |
43 | hsa-miR-20a-5p | BNIP3L | 0.85 | 0 | -0.67 | 0 | MirTarget | -0.2 | 0 | NA | |
44 | hsa-miR-20a-5p | BTN3A1 | 0.85 | 0 | 0.33 | 0.01478 | miRNAWalker2 validate | -0.21 | 0 | NA | |
45 | hsa-miR-20a-5p | C16orf52 | 0.85 | 0 | -0.5 | 0 | miRNATAP | -0.18 | 0 | NA | |
46 | hsa-miR-20a-5p | C16orf70 | 0.85 | 0 | -0.77 | 0 | miRNATAP | -0.11 | 0.00075 | NA | |
47 | hsa-miR-20a-5p | C2CD2 | 0.85 | 0 | 0.04 | 0.76174 | MirTarget; miRNATAP | -0.19 | 0 | NA | |
48 | hsa-miR-20a-5p | CA5B | 0.85 | 0 | 0.77 | 1.0E-5 | mirMAP | -0.16 | 0.00143 | NA | |
49 | hsa-miR-20a-5p | CALD1 | 0.85 | 0 | -0.53 | 0 | miRNATAP | -0.2 | 0 | NA | |
50 | hsa-miR-20a-5p | CAMTA2 | 0.85 | 0 | -0.35 | 8.0E-5 | MirTarget | -0.11 | 1.0E-5 | NA | |
51 | hsa-miR-20a-5p | CASC4 | 0.85 | 0 | -0.46 | 0 | MirTarget | -0.19 | 0 | NA | |
52 | hsa-miR-20a-5p | CASK | 0.85 | 0 | 0.43 | 0.00011 | mirMAP | -0.2 | 0 | NA | |
53 | hsa-miR-20a-5p | CAV1 | 0.85 | 0 | 0.18 | 0.17977 | miRNATAP | -0.17 | 0 | NA | |
54 | hsa-miR-20a-5p | CAV2 | 0.85 | 0 | -0.67 | 0.00155 | mirMAP | -0.33 | 0 | NA | |
55 | hsa-miR-20a-5p | CBLN4 | 0.85 | 0 | -1.67 | 0.00015 | miRNATAP | -0.55 | 1.0E-5 | NA | |
56 | hsa-miR-20a-5p | CBX7 | 0.85 | 0 | -0.08 | 0.52937 | mirMAP | -0.17 | 0 | NA | |
57 | hsa-miR-20a-5p | CC2D1A | 0.85 | 0 | 0.26 | 0.00869 | MirTarget; miRNATAP | -0.12 | 2.0E-5 | NA | |
58 | hsa-miR-20a-5p | CCBE1 | 0.85 | 0 | -5.46 | 0 | mirMAP | -0.64 | 0 | NA | |
59 | hsa-miR-20a-5p | CCDC103 | 0.85 | 0 | -0.03 | 0.84263 | mirMAP | -0.14 | 0.0048 | NA | |
60 | hsa-miR-20a-5p | CCND1 | 0.85 | 0 | -0.9 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.33 | 0 | NA | |
61 | hsa-miR-20a-5p | CCND2 | 0.85 | 0 | 0.36 | 0.03656 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.16 | 0.00121 | NA | |
62 | hsa-miR-20a-5p | CD274 | 0.85 | 0 | -1.27 | 0 | MirTarget; miRNATAP | -0.42 | 0 | NA | |
63 | hsa-miR-20a-5p | CD69 | 0.85 | 0 | -1.75 | 0 | miRNATAP | -0.22 | 0.00265 | NA | |
64 | hsa-miR-20a-5p | CDC37L1 | 0.85 | 0 | -1.68 | 0 | MirTarget; miRNATAP | -0.32 | 0 | NA | |
65 | hsa-miR-20a-5p | CDK6 | 0.85 | 0 | -0.31 | 0.22057 | mirMAP | -0.34 | 0 | NA | |
66 | hsa-miR-20a-5p | CDKN1A | 0.85 | 0 | -0.77 | 6.0E-5 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.28 | 0 | 26012475 | Using the poorly tumorigenic and TGF-β-sensitive FET cell line that expresses low miR-20a levels we first confirmed that miR-20a downmodulated CDKN1A expression both at mRNA and protein level through direct binding to its 3'-UTR; Moreover besides modulating CDKN1A miR-20a blocked TGF-β-induced transactivation of its promoter without affecting the post-receptor activation of Smad3/4 effectors directly; Finally miR-20a abrogated the TGF-β-mediated c-Myc repression a direct inhibitor of the CDKN1A promoter activation most likely by reducing the expression of specific MYC-regulating genes from the Smad/E2F-based core repressor complex |
67 | hsa-miR-20a-5p | CELF2 | 0.85 | 0 | -0.74 | 8.0E-5 | miRNATAP | -0.22 | 2.0E-5 | NA | |
68 | hsa-miR-20a-5p | CEP97 | 0.85 | 0 | 0.29 | 0.07184 | MirTarget; miRNATAP | -0.12 | 0.00766 | NA | |
69 | hsa-miR-20a-5p | CERCAM | 0.85 | 0 | -0.12 | 0.64816 | MirTarget | -0.19 | 0.00968 | NA | |
70 | hsa-miR-20a-5p | CFL2 | 0.85 | 0 | -1.18 | 0 | MirTarget; miRNATAP | -0.16 | 3.0E-5 | NA | |
71 | hsa-miR-20a-5p | CHD9 | 0.85 | 0 | -0.51 | 3.0E-5 | MirTarget; miRNATAP | -0.24 | 0 | NA | |
72 | hsa-miR-20a-5p | CIITA | 0.85 | 0 | 0.27 | 0.18011 | mirMAP | -0.19 | 0.00094 | NA | |
73 | hsa-miR-20a-5p | CLIC6 | 0.85 | 0 | -3.64 | 0 | mirMAP | -0.73 | 0 | NA | |
74 | hsa-miR-20a-5p | CLIP4 | 0.85 | 0 | -0.22 | 0.43954 | MirTarget | -0.3 | 0.00021 | NA | |
75 | hsa-miR-20a-5p | CLOCK | 0.85 | 0 | -0.53 | 0.00745 | MirTarget | -0.28 | 0 | NA | |
76 | hsa-miR-20a-5p | CMPK1 | 0.85 | 0 | -0.68 | 0 | MirTarget; miRNATAP | -0.15 | 0 | NA | |
77 | hsa-miR-20a-5p | CNDP1 | 0.85 | 0 | -6.39 | 0 | mirMAP | -0.71 | 7.0E-5 | NA | |
78 | hsa-miR-20a-5p | CNTNAP3 | 0.85 | 0 | 0.11 | 0.74285 | MirTarget | -0.36 | 7.0E-5 | NA | |
79 | hsa-miR-20a-5p | COL1A1 | 0.85 | 0 | 0.83 | 0.00649 | mirMAP | -0.23 | 0.0068 | NA | |
80 | hsa-miR-20a-5p | COL4A3 | 0.85 | 0 | -0.93 | 0.00622 | MirTarget; miRNATAP | -0.28 | 0.00414 | NA | |
81 | hsa-miR-20a-5p | COL8A2 | 0.85 | 0 | -0.97 | 0.0009 | mirMAP | -0.23 | 0.00524 | NA | |
82 | hsa-miR-20a-5p | CORO2B | 0.85 | 0 | -0.78 | 0.00171 | MirTarget; miRNATAP | -0.17 | 0.01392 | NA | |
83 | hsa-miR-20a-5p | CPEB3 | 0.85 | 0 | -2.74 | 0 | miRNATAP | -0.45 | 0 | NA | |
84 | hsa-miR-20a-5p | CPEB4 | 0.85 | 0 | -1.06 | 0 | mirMAP | -0.22 | 0 | NA | |
85 | hsa-miR-20a-5p | CREB5 | 0.85 | 0 | 0 | 0.99313 | MirTarget; miRNATAP | -0.15 | 0.01025 | NA | |
86 | hsa-miR-20a-5p | CRIM1 | 0.85 | 0 | -0.43 | 0.03963 | miRTarBase; MirTarget; miRNATAP | -0.44 | 0 | NA | |
87 | hsa-miR-20a-5p | CRK | 0.85 | 0 | -0.66 | 0 | MirTarget; miRNATAP | -0.12 | 5.0E-5 | NA | |
88 | hsa-miR-20a-5p | CRYBG3 | 0.85 | 0 | -0.7 | 0.01151 | MirTarget; miRNATAP | -0.48 | 0 | NA | |
89 | hsa-miR-20a-5p | CSF1 | 0.85 | 0 | -0.59 | 0.00153 | miRNATAP | -0.28 | 0 | NA | |
90 | hsa-miR-20a-5p | CSGALNACT1 | 0.85 | 0 | 0.19 | 0.22912 | MirTarget | -0.21 | 0 | NA | |
91 | hsa-miR-20a-5p | CXCL6 | 0.85 | 0 | -3.43 | 0 | MirTarget | -0.84 | 0 | NA | |
92 | hsa-miR-20a-5p | CXorf23 | 0.85 | 0 | 0.43 | 1.0E-5 | mirMAP | -0.1 | 0.00027 | NA | |
93 | hsa-miR-20a-5p | CXorf38 | 0.85 | 0 | -0.21 | 0.02517 | mirMAP | -0.13 | 0 | NA | |
94 | hsa-miR-20a-5p | CYBRD1 | 0.85 | 0 | -1.29 | 0 | MirTarget | -0.37 | 0 | NA | |
95 | hsa-miR-20a-5p | CYP2U1 | 0.85 | 0 | -1.02 | 0 | MirTarget | -0.33 | 0 | NA | |
96 | hsa-miR-20a-5p | DAB2 | 0.85 | 0 | -0.08 | 0.65939 | MirTarget; miRNATAP | -0.15 | 0.00404 | NA | |
97 | hsa-miR-20a-5p | DAZAP2 | 0.85 | 0 | -0.39 | 0 | MirTarget; miRNATAP | -0.11 | 0 | NA | |
98 | hsa-miR-20a-5p | DCUN1D3 | 0.85 | 0 | -1.25 | 0 | MirTarget | -0.16 | 0 | NA | |
99 | hsa-miR-20a-5p | DGKE | 0.85 | 0 | -0.86 | 0 | MirTarget | -0.23 | 1.0E-5 | NA | |
100 | hsa-miR-20a-5p | DIP2C | 0.85 | 0 | -0.78 | 5.0E-5 | miRNATAP | -0.25 | 0 | NA | |
101 | hsa-miR-20a-5p | DIRC2 | 0.85 | 0 | -0.06 | 0.49043 | MirTarget; miRNATAP | -0.22 | 0 | NA | |
102 | hsa-miR-20a-5p | DIXDC1 | 0.85 | 0 | -1.03 | 0 | mirMAP | -0.28 | 0 | NA | |
103 | hsa-miR-20a-5p | DLC1 | 0.85 | 0 | -1.42 | 0 | miRNAWalker2 validate; miRNATAP | -0.18 | 4.0E-5 | NA | |
104 | hsa-miR-20a-5p | DLG2 | 0.85 | 0 | -1.95 | 0 | mirMAP | -0.37 | 0 | NA | |
105 | hsa-miR-20a-5p | DMD | 0.85 | 0 | -1.66 | 0 | mirMAP | -0.28 | 0 | NA | |
106 | hsa-miR-20a-5p | DNAJB9 | 0.85 | 0 | -0.63 | 0 | miRNATAP | -0.2 | 0 | NA | |
107 | hsa-miR-20a-5p | DNAJC27 | 0.85 | 0 | -0.35 | 0.00026 | MirTarget; miRNATAP | -0.14 | 0 | NA | |
108 | hsa-miR-20a-5p | DOCK4 | 0.85 | 0 | -0.2 | 0.07305 | MirTarget | -0.14 | 1.0E-5 | NA | |
109 | hsa-miR-20a-5p | DPYSL2 | 0.85 | 0 | -0.46 | 0.00089 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
110 | hsa-miR-20a-5p | DYNC1LI2 | 0.85 | 0 | -0.06 | 0.41267 | MirTarget; miRNATAP | -0.12 | 0 | NA | |
111 | hsa-miR-20a-5p | EDA2R | 0.85 | 0 | 0.56 | 0.06663 | MirTarget | -0.35 | 4.0E-5 | NA | |
112 | hsa-miR-20a-5p | EDEM1 | 0.85 | 0 | -0.85 | 0 | mirMAP | -0.17 | 0 | NA | |
113 | hsa-miR-20a-5p | EFNB1 | 0.85 | 0 | -0.04 | 0.75638 | miRNATAP | -0.13 | 7.0E-5 | NA | |
114 | hsa-miR-20a-5p | EGR2 | 0.85 | 0 | -2.93 | 0 | MirTarget; miRNATAP | -0.39 | 0 | 23924943 | Involvement of miR 20a in promoting gastric cancer progression by targeting early growth response 2 EGR2; Luciferase activity and Western blot confirmed that miR-20a negatively regulated EGR2 expression; Overexpression of EGR2 significantly attenuated the oncogenic effect of miR-20a miR-20a was involved in the carcinogenesis of GC through modulation of the EGR2 signaling pathway |
115 | hsa-miR-20a-5p | ELK3 | 0.85 | 0 | -0.37 | 0.06773 | MirTarget; miRNATAP | -0.26 | 1.0E-5 | NA | |
116 | hsa-miR-20a-5p | ELK4 | 0.85 | 0 | 0.24 | 0.02672 | miRNATAP | -0.13 | 1.0E-5 | NA | |
117 | hsa-miR-20a-5p | EPAS1 | 0.85 | 0 | -0.88 | 0 | miRNATAP | -0.13 | 2.0E-5 | NA | |
118 | hsa-miR-20a-5p | EPHA4 | 0.85 | 0 | -0.01 | 0.94622 | miRNATAP | -0.21 | 0.00021 | NA | |
119 | hsa-miR-20a-5p | ERAP1 | 0.85 | 0 | -0.06 | 0.66413 | MirTarget | -0.16 | 1.0E-5 | NA | |
120 | hsa-miR-20a-5p | ESYT2 | 0.85 | 0 | -0.17 | 0.03903 | mirMAP | -0.14 | 0 | NA | |
121 | hsa-miR-20a-5p | ETV1 | 0.85 | 0 | -0.47 | 0.05217 | MirTarget; miRNATAP | -0.24 | 0.00042 | NA | |
122 | hsa-miR-20a-5p | F3 | 0.85 | 0 | -1.78 | 0 | MirTarget; miRNATAP | -0.17 | 0.02735 | NA | |
123 | hsa-miR-20a-5p | FAM129B | 0.85 | 0 | -0.13 | 0.41634 | miRNATAP | -0.15 | 0.00107 | NA | |
124 | hsa-miR-20a-5p | FAM46C | 0.85 | 0 | -1.66 | 0 | MirTarget; miRNATAP | -0.24 | 0.00024 | NA | |
125 | hsa-miR-20a-5p | FAT4 | 0.85 | 0 | -1.89 | 0 | MirTarget; miRNATAP | -0.5 | 0 | NA | |
126 | hsa-miR-20a-5p | FBXL5 | 0.85 | 0 | -0.36 | 0.00059 | miRNATAP | -0.21 | 0 | NA | |
127 | hsa-miR-20a-5p | FBXO28 | 0.85 | 0 | -0.5 | 0 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
128 | hsa-miR-20a-5p | FBXO3 | 0.85 | 0 | -0.54 | 0 | miRNAWalker2 validate; mirMAP | -0.13 | 0 | 25115392 | F box protein FBXO31 is down regulated in gastric cancer and negatively regulated by miR 17 and miR 20a; miR-20a and miR-17 directly bind to the 3'-UTR of FBXO31; Moreover a highly significant negative correlation between miR-20a miR-17 and FBXO31 was observed in these GC samples |
129 | hsa-miR-20a-5p | FBXO31 | 0.85 | 0 | -0.1 | 0.57277 | MirTarget | -0.17 | 0.00046 | 25115392 | F box protein FBXO31 is down regulated in gastric cancer and negatively regulated by miR 17 and miR 20a; miR-20a and miR-17 directly bind to the 3'-UTR of FBXO31; Moreover a highly significant negative correlation between miR-20a miR-17 and FBXO31 was observed in these GC samples |
130 | hsa-miR-20a-5p | FEM1C | 0.85 | 0 | -0.5 | 0 | MirTarget; miRNATAP | -0.1 | 0.00025 | NA | |
131 | hsa-miR-20a-5p | FGD4 | 0.85 | 0 | -1.16 | 0 | MirTarget | -0.34 | 0 | NA | |
132 | hsa-miR-20a-5p | FGD5 | 0.85 | 0 | -0.09 | 0.58163 | MirTarget; miRNATAP | -0.12 | 0.00712 | NA | |
133 | hsa-miR-20a-5p | FGF7 | 0.85 | 0 | -0.65 | 0.00602 | miRNAWalker2 validate | -0.34 | 0 | NA | |
134 | hsa-miR-20a-5p | FGFR1 | 0.85 | 0 | -1.1 | 0 | mirMAP | -0.29 | 0 | NA | |
135 | hsa-miR-20a-5p | FGL2 | 0.85 | 0 | -1.57 | 0 | MirTarget | -0.3 | 0 | NA | |
136 | hsa-miR-20a-5p | FHL2 | 0.85 | 0 | -1.49 | 0 | mirMAP | -0.57 | 0 | NA | |
137 | hsa-miR-20a-5p | FIBIN | 0.85 | 0 | -1.09 | 0.00125 | MirTarget | -0.38 | 7.0E-5 | NA | |
138 | hsa-miR-20a-5p | FJX1 | 0.85 | 0 | -0.06 | 0.72199 | MirTarget; miRNATAP | -0.16 | 0.00056 | NA | |
139 | hsa-miR-20a-5p | FKBP5 | 0.85 | 0 | -0.23 | 0.1942 | mirMAP | -0.23 | 0 | NA | |
140 | hsa-miR-20a-5p | FLNA | 0.85 | 0 | 0.23 | 0.20343 | miRNAWalker2 validate | -0.24 | 0 | NA | |
141 | hsa-miR-20a-5p | FLT1 | 0.85 | 0 | 0.35 | 0.00776 | MirTarget; miRNATAP | -0.12 | 0.00085 | NA | |
142 | hsa-miR-20a-5p | FMN1 | 0.85 | 0 | -0.64 | 0.02771 | mirMAP | -0.4 | 0 | NA | |
143 | hsa-miR-20a-5p | FNDC3A | 0.85 | 0 | -1 | 0 | MirTarget; miRNATAP | -0.16 | 3.0E-5 | NA | |
144 | hsa-miR-20a-5p | FNIP2 | 0.85 | 0 | -1.97 | 0 | MirTarget | -0.23 | 0.00283 | NA | |
145 | hsa-miR-20a-5p | FOXJ2 | 0.85 | 0 | 0.02 | 0.81272 | MirTarget; miRNATAP | -0.11 | 3.0E-5 | NA | |
146 | hsa-miR-20a-5p | FRMD6 | 0.85 | 0 | -1.21 | 0 | MirTarget; miRNATAP | -0.28 | 0 | NA | |
147 | hsa-miR-20a-5p | FTO | 0.85 | 0 | -0.23 | 0.00923 | mirMAP | -0.17 | 0 | NA | |
148 | hsa-miR-20a-5p | FYCO1 | 0.85 | 0 | -0.01 | 0.88337 | MirTarget | -0.19 | 0 | NA | |
149 | hsa-miR-20a-5p | FYN | 0.85 | 0 | -1.06 | 0 | miRNATAP | -0.23 | 0 | NA | |
150 | hsa-miR-20a-5p | FZD3 | 0.85 | 0 | -0.43 | 0.07605 | MirTarget; mirMAP; miRNATAP | -0.26 | 0.00012 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TISSUE DEVELOPMENT | 93 | 1518 | 9.586e-16 | 4.461e-12 |
2 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 92 | 1672 | 8.245e-13 | 1.918e-09 |
3 | ORGAN MORPHOGENESIS | 59 | 841 | 1.41e-12 | 2.187e-09 |
4 | REGULATION OF CELL DIFFERENTIATION | 84 | 1492 | 3.003e-12 | 2.795e-09 |
5 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 84 | 1492 | 3.003e-12 | 2.795e-09 |
6 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 55 | 771 | 4.526e-12 | 3.51e-09 |
7 | EPITHELIUM DEVELOPMENT | 61 | 945 | 1.9e-11 | 1.263e-08 |
8 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 64 | 1036 | 3.745e-11 | 1.584e-08 |
9 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 64 | 1036 | 3.745e-11 | 1.584e-08 |
10 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 68 | 1135 | 3.303e-11 | 1.584e-08 |
11 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 86 | 1618 | 3.281e-11 | 1.584e-08 |
12 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 91 | 1791 | 8.763e-11 | 3.137e-08 |
13 | CELL DEVELOPMENT | 78 | 1426 | 8.267e-11 | 3.137e-08 |
14 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 67 | 1142 | 1.158e-10 | 3.847e-08 |
15 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 80 | 1518 | 2.722e-10 | 8.444e-08 |
16 | POSITIVE REGULATION OF CELL DEVELOPMENT | 38 | 472 | 3.815e-10 | 1.044e-07 |
17 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 89 | 1784 | 3.771e-10 | 1.044e-07 |
18 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 61 | 1021 | 4.267e-10 | 1.103e-07 |
19 | TUBE DEVELOPMENT | 41 | 552 | 8.565e-10 | 1.985e-07 |
20 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 51 | 788 | 8.958e-10 | 1.985e-07 |
21 | CIRCULATORY SYSTEM DEVELOPMENT | 51 | 788 | 8.958e-10 | 1.985e-07 |
22 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 39 | 513 | 1.163e-09 | 2.45e-07 |
23 | REGULATION OF PROTEIN MODIFICATION PROCESS | 85 | 1710 | 1.211e-09 | 2.45e-07 |
24 | REGULATION OF KINASE ACTIVITY | 50 | 776 | 1.54e-09 | 2.937e-07 |
25 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 54 | 876 | 1.578e-09 | 2.937e-07 |
26 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 92 | 1929 | 1.805e-09 | 3.23e-07 |
27 | POSITIVE REGULATION OF CELL COMMUNICATION | 78 | 1532 | 2.279e-09 | 3.928e-07 |
28 | REGULATION OF CELL DEVELOPMENT | 52 | 836 | 2.389e-09 | 3.97e-07 |
29 | POSITIVE REGULATION OF LOCOMOTION | 34 | 420 | 2.869e-09 | 4.604e-07 |
30 | INTRACELLULAR SIGNAL TRANSDUCTION | 79 | 1572 | 3.184e-09 | 4.939e-07 |
31 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 72 | 1395 | 5.903e-09 | 8.861e-07 |
32 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 81 | 1656 | 6.659e-09 | 9.683e-07 |
33 | NEUROGENESIS | 72 | 1402 | 7.271e-09 | 1.025e-06 |
34 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 34 | 437 | 7.835e-09 | 1.042e-06 |
35 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 47 | 740 | 7.733e-09 | 1.042e-06 |
36 | POSITIVE REGULATION OF GENE EXPRESSION | 83 | 1733 | 1.095e-08 | 1.415e-06 |
37 | CELL PROJECTION ORGANIZATION | 53 | 902 | 1.161e-08 | 1.46e-06 |
38 | VASCULATURE DEVELOPMENT | 35 | 469 | 1.362e-08 | 1.668e-06 |
39 | POSITIVE REGULATION OF MAPK CASCADE | 35 | 470 | 1.438e-08 | 1.715e-06 |
40 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 23 | 229 | 2.201e-08 | 2.407e-06 |
41 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 27 | 306 | 2.125e-08 | 2.407e-06 |
42 | REGULATION OF TRANSFERASE ACTIVITY | 54 | 946 | 2.225e-08 | 2.407e-06 |
43 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 30 | 368 | 2.133e-08 | 2.407e-06 |
44 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 56 | 1004 | 2.649e-08 | 2.739e-06 |
45 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 51 | 872 | 2.601e-08 | 2.739e-06 |
46 | POSITIVE REGULATION OF KINASE ACTIVITY | 35 | 482 | 2.709e-08 | 2.74e-06 |
47 | TISSUE MORPHOGENESIS | 37 | 533 | 3.472e-08 | 3.437e-06 |
48 | NEURON PROJECTION MORPHOGENESIS | 31 | 402 | 4.453e-08 | 4.317e-06 |
49 | REGULATION OF MAPK CASCADE | 42 | 660 | 4.784e-08 | 4.452e-06 |
50 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 34 | 470 | 4.714e-08 | 4.452e-06 |
51 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 43 | 689 | 5.712e-08 | 5.212e-06 |
52 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 83 | 1805 | 6.665e-08 | 5.964e-06 |
53 | MUSCLE STRUCTURE DEVELOPMENT | 32 | 432 | 6.859e-08 | 6.022e-06 |
54 | CELLULAR COMPONENT MORPHOGENESIS | 51 | 900 | 7.103e-08 | 6.121e-06 |
55 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 45 | 750 | 8.712e-08 | 7.37e-06 |
56 | REGULATION OF NEURON DIFFERENTIATION | 37 | 554 | 9.307e-08 | 7.733e-06 |
57 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 64 | 1275 | 1.272e-07 | 1.038e-05 |
58 | MUSCLE TISSUE DEVELOPMENT | 24 | 275 | 1.595e-07 | 1.258e-05 |
59 | LOCOMOTION | 58 | 1114 | 1.572e-07 | 1.258e-05 |
60 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 39 | 616 | 1.678e-07 | 1.301e-05 |
61 | NEURON PROJECTION DEVELOPMENT | 36 | 545 | 1.827e-07 | 1.371e-05 |
62 | NEURON DIFFERENTIATION | 49 | 874 | 1.799e-07 | 1.371e-05 |
63 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 47 | 823 | 1.91e-07 | 1.389e-05 |
64 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 53 | 983 | 1.904e-07 | 1.389e-05 |
65 | SKELETAL SYSTEM DEVELOPMENT | 32 | 455 | 2.232e-07 | 1.598e-05 |
66 | CYTOSKELETON ORGANIZATION | 47 | 838 | 3.218e-07 | 2.269e-05 |
67 | HEAD DEVELOPMENT | 42 | 709 | 3.369e-07 | 2.34e-05 |
68 | MORPHOGENESIS OF AN EPITHELIUM | 29 | 400 | 4.451e-07 | 3.045e-05 |
69 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 21 | 232 | 5.209e-07 | 3.513e-05 |
70 | ACTIN FILAMENT BASED PROCESS | 31 | 450 | 5.412e-07 | 3.598e-05 |
71 | RESPONSE TO ENDOGENOUS STIMULUS | 68 | 1450 | 6.101e-07 | 3.998e-05 |
72 | MUSCLE CELL DIFFERENTIATION | 21 | 237 | 7.399e-07 | 4.782e-05 |
73 | CELL PART MORPHOGENESIS | 38 | 633 | 9.034e-07 | 5.72e-05 |
74 | REGULATION OF CELL PROLIFERATION | 69 | 1496 | 9.097e-07 | 5.72e-05 |
75 | NEURON DEVELOPMENT | 40 | 687 | 1.002e-06 | 6.216e-05 |
76 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 50 | 957 | 1.088e-06 | 6.663e-05 |
77 | HEART DEVELOPMENT | 31 | 466 | 1.139e-06 | 6.882e-05 |
78 | TELENCEPHALON DEVELOPMENT | 20 | 228 | 1.587e-06 | 9.465e-05 |
79 | NEGATIVE REGULATION OF GENE EXPRESSION | 68 | 1493 | 1.714e-06 | 0.000101 |
80 | HEART MORPHOGENESIS | 19 | 212 | 2.098e-06 | 0.000122 |
81 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 56 | 1152 | 2.263e-06 | 0.00013 |
82 | BONE DEVELOPMENT | 16 | 156 | 2.334e-06 | 0.0001325 |
83 | REGULATION OF CELL PROJECTION ORGANIZATION | 34 | 558 | 2.48e-06 | 0.000139 |
84 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 79 | 1848 | 2.622e-06 | 0.0001452 |
85 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 15 | 140 | 2.792e-06 | 0.0001528 |
86 | TRANSITION METAL ION HOMEOSTASIS | 13 | 106 | 2.843e-06 | 0.0001538 |
87 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 43 | 801 | 3.239e-06 | 0.0001713 |
88 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 23 | 303 | 3.236e-06 | 0.0001713 |
89 | NEGATIVE REGULATION OF CELL PROLIFERATION | 37 | 643 | 3.384e-06 | 0.0001769 |
90 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 16 | 162 | 3.829e-06 | 0.000198 |
91 | REGULATION OF HYDROLASE ACTIVITY | 61 | 1327 | 4.657e-06 | 0.0002381 |
92 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 22 | 289 | 5.044e-06 | 0.0002551 |
93 | FOREBRAIN DEVELOPMENT | 25 | 357 | 5.128e-06 | 0.0002566 |
94 | REGULATION OF CELL MORPHOGENESIS | 33 | 552 | 5.223e-06 | 0.0002585 |
95 | POSITIVE REGULATION OF CELL DEATH | 35 | 605 | 5.565e-06 | 0.0002726 |
96 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 24 | 337 | 5.95e-06 | 0.0002884 |
97 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 27 | 408 | 6.178e-06 | 0.0002964 |
98 | GLAND MORPHOGENESIS | 12 | 97 | 6.243e-06 | 0.0002964 |
99 | BLOOD VESSEL MORPHOGENESIS | 25 | 364 | 7.191e-06 | 0.000338 |
100 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 14 | 133 | 7.348e-06 | 0.0003401 |
101 | PHOSPHORYLATION | 57 | 1228 | 7.383e-06 | 0.0003401 |
102 | REGULATION OF MAP KINASE ACTIVITY | 23 | 319 | 7.59e-06 | 0.0003462 |
103 | PROTEIN PHOSPHORYLATION | 47 | 944 | 8.387e-06 | 0.0003789 |
104 | STRIATED MUSCLE CELL DIFFERENTIATION | 16 | 173 | 8.924e-06 | 0.0003955 |
105 | REGULATION OF CELL SUBSTRATE ADHESION | 16 | 173 | 8.924e-06 | 0.0003955 |
106 | CELL MOTILITY | 43 | 835 | 9.126e-06 | 0.0003969 |
107 | LOCALIZATION OF CELL | 43 | 835 | 9.126e-06 | 0.0003969 |
108 | TUBE MORPHOGENESIS | 23 | 323 | 9.3e-06 | 0.0004007 |
109 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 81 | 1977 | 9.543e-06 | 0.0004074 |
110 | EPITHELIAL CELL DIFFERENTIATION | 30 | 495 | 1.079e-05 | 0.0004564 |
111 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 12 | 103 | 1.167e-05 | 0.0004893 |
112 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 30 | 498 | 1.212e-05 | 0.0005035 |
113 | REGULATION OF CELL ADHESION | 35 | 629 | 1.284e-05 | 0.0005241 |
114 | NEGATIVE REGULATION OF CELL COMMUNICATION | 55 | 1192 | 1.28e-05 | 0.0005241 |
115 | REGULATION OF CHEMOTAXIS | 16 | 180 | 1.473e-05 | 0.0005959 |
116 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 26 | 404 | 1.493e-05 | 0.000599 |
117 | REGULATION OF CELL DEATH | 64 | 1472 | 1.574e-05 | 0.0006259 |
118 | REGULATION OF CELL MATRIX ADHESION | 11 | 90 | 1.703e-05 | 0.0006661 |
119 | MESONEPHROS DEVELOPMENT | 11 | 90 | 1.703e-05 | 0.0006661 |
120 | KIDNEY EPITHELIUM DEVELOPMENT | 13 | 125 | 1.767e-05 | 0.0006853 |
121 | NEURON PROJECTION GUIDANCE | 17 | 205 | 1.992e-05 | 0.0007661 |
122 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 48 | 1008 | 2.133e-05 | 0.0008135 |
123 | EPITHELIAL CELL DEVELOPMENT | 16 | 186 | 2.216e-05 | 0.0008382 |
124 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 17 | 207 | 2.258e-05 | 0.0008475 |
125 | RESPONSE TO MECHANICAL STIMULUS | 17 | 210 | 2.717e-05 | 0.001011 |
126 | REGULATION OF VASCULATURE DEVELOPMENT | 18 | 233 | 2.972e-05 | 0.001097 |
127 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 59 | 1360 | 3.708e-05 | 0.001358 |
128 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 33 | 609 | 3.841e-05 | 0.001391 |
129 | BIOLOGICAL ADHESION | 48 | 1032 | 3.856e-05 | 0.001391 |
130 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 64 | 1517 | 3.931e-05 | 0.001396 |
131 | REGULATION OF BINDING | 20 | 283 | 3.925e-05 | 0.001396 |
132 | EMBRYONIC ORGAN DEVELOPMENT | 25 | 406 | 4.501e-05 | 0.001587 |
133 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 37 | 724 | 4.577e-05 | 0.001589 |
134 | ACTIVATION OF MAPKK ACTIVITY | 8 | 52 | 4.555e-05 | 0.001589 |
135 | EMBRYO DEVELOPMENT | 43 | 894 | 4.62e-05 | 0.001592 |
136 | TRABECULA MORPHOGENESIS | 7 | 39 | 4.912e-05 | 0.001681 |
137 | REGULATION OF OSSIFICATION | 15 | 178 | 5.044e-05 | 0.001713 |
138 | REGULATION OF DEVELOPMENTAL GROWTH | 20 | 289 | 5.268e-05 | 0.001763 |
139 | ORGAN GROWTH | 9 | 68 | 5.256e-05 | 0.001763 |
140 | POSITIVE REGULATION OF CELL PROLIFERATION | 40 | 814 | 5.371e-05 | 0.001785 |
141 | REGULATION OF JNK CASCADE | 14 | 159 | 5.539e-05 | 0.001828 |
142 | SKELETAL SYSTEM MORPHOGENESIS | 16 | 201 | 5.698e-05 | 0.001867 |
143 | IRON ION HOMEOSTASIS | 9 | 69 | 5.911e-05 | 0.001923 |
144 | TAXIS | 27 | 464 | 5.958e-05 | 0.001925 |
145 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 43 | 905 | 6.111e-05 | 0.001961 |
146 | CARDIAC CHAMBER MORPHOGENESIS | 11 | 104 | 6.644e-05 | 0.002091 |
147 | SENSORY ORGAN DEVELOPMENT | 28 | 493 | 6.65e-05 | 0.002091 |
148 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 9 | 70 | 6.633e-05 | 0.002091 |
149 | WOUND HEALING | 27 | 470 | 7.396e-05 | 0.00231 |
150 | CARDIAC CHAMBER DEVELOPMENT | 13 | 144 | 7.854e-05 | 0.002436 |
151 | UROGENITAL SYSTEM DEVELOPMENT | 20 | 299 | 8.431e-05 | 0.002598 |
152 | REGULATION OF EPITHELIAL CELL MIGRATION | 14 | 166 | 8.843e-05 | 0.002689 |
153 | RESPONSE TO GROWTH FACTOR | 27 | 475 | 8.824e-05 | 0.002689 |
154 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 19 | 278 | 9.504e-05 | 0.002871 |
155 | CARTILAGE DEVELOPMENT | 13 | 147 | 9.699e-05 | 0.002912 |
156 | EMBRYONIC ORGAN MORPHOGENESIS | 19 | 279 | 9.964e-05 | 0.002972 |
157 | CARDIAC MUSCLE CELL DIFFERENTIATION | 9 | 74 | 0.0001031 | 0.003036 |
158 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 22 | 352 | 0.0001028 | 0.003036 |
159 | EMBRYONIC HEMOPOIESIS | 5 | 20 | 0.0001161 | 0.003376 |
160 | RESPONSE TO WOUNDING | 30 | 563 | 0.0001159 | 0.003376 |
161 | COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 11 | 111 | 0.0001203 | 0.003476 |
162 | EMBRYONIC MORPHOGENESIS | 29 | 539 | 0.0001273 | 0.003612 |
163 | RESPONSE TO ABIOTIC STIMULUS | 46 | 1024 | 0.0001268 | 0.003612 |
164 | ENDOCHONDRAL BONE MORPHOGENESIS | 7 | 45 | 0.0001271 | 0.003612 |
165 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 19 | 285 | 0.0001316 | 0.003711 |
166 | CONNECTIVE TISSUE DEVELOPMENT | 15 | 194 | 0.0001335 | 0.003743 |
167 | REGULATION OF BMP SIGNALING PATHWAY | 9 | 77 | 0.0001407 | 0.00392 |
168 | PALLIUM DEVELOPMENT | 13 | 153 | 0.0001454 | 0.004027 |
169 | REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 5 | 21 | 0.0001492 | 0.004108 |
170 | HOMEOSTASIS OF NUMBER OF CELLS | 14 | 175 | 0.0001551 | 0.004246 |
171 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 15 | 197 | 0.0001582 | 0.00428 |
172 | RESPIRATORY SYSTEM DEVELOPMENT | 15 | 197 | 0.0001582 | 0.00428 |
173 | CARDIOCYTE DIFFERENTIATION | 10 | 96 | 0.0001609 | 0.004327 |
174 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 12 | 135 | 0.00017 | 0.004521 |
175 | RESPONSE TO EXTERNAL STIMULUS | 71 | 1821 | 0.0001697 | 0.004521 |
176 | BONE MORPHOGENESIS | 9 | 79 | 0.0001717 | 0.004538 |
177 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 13 | 156 | 0.0001765 | 0.004641 |
178 | RESPONSE TO STEROID HORMONE | 27 | 497 | 0.000185 | 0.004837 |
179 | RESPONSE TO HORMONE | 41 | 893 | 0.0001885 | 0.004901 |
180 | REGULATION OF PROTEIN CATABOLIC PROCESS | 23 | 393 | 0.0001905 | 0.004924 |
181 | REGULATION OF LIPID KINASE ACTIVITY | 7 | 48 | 0.0001932 | 0.004966 |
182 | REGULATION OF HOMEOSTATIC PROCESS | 25 | 447 | 0.0002049 | 0.005212 |
183 | POSITIVE REGULATION OF CATABOLIC PROCESS | 23 | 395 | 0.000205 | 0.005212 |
184 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 10 | 99 | 0.0002077 | 0.005224 |
185 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 10 | 99 | 0.0002077 | 0.005224 |
186 | REGULATION OF BODY FLUID LEVELS | 27 | 506 | 0.0002465 | 0.006165 |
187 | REGULATION OF GTPASE ACTIVITY | 33 | 673 | 0.0002513 | 0.006252 |
188 | REGULATION OF CATABOLIC PROCESS | 35 | 731 | 0.0002572 | 0.006365 |
189 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 11 | 121 | 0.0002587 | 0.006369 |
190 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 14 | 184 | 0.0002616 | 0.006404 |
191 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 6 | 36 | 0.0002629 | 0.006404 |
192 | HOMEOSTATIC PROCESS | 55 | 1337 | 0.0002695 | 0.006531 |
193 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 15 | 207 | 0.0002714 | 0.006543 |
194 | REGULATION OF CELLULAR LOCALIZATION | 53 | 1277 | 0.0002827 | 0.006781 |
195 | RESPONSE TO DRUG | 24 | 431 | 0.000291 | 0.006944 |
196 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 18 | 279 | 0.000293 | 0.006957 |
197 | CARDIAC SEPTUM DEVELOPMENT | 9 | 85 | 0.0003004 | 0.007095 |
198 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 12 | 144 | 0.0003104 | 0.007279 |
199 | NEGATIVE REGULATION OF CELL CYCLE | 24 | 433 | 0.0003113 | 0.007279 |
200 | REGULATION OF LIPID METABOLIC PROCESS | 18 | 282 | 0.0003334 | 0.007757 |
201 | CEREBRAL CORTEX DEVELOPMENT | 10 | 105 | 0.0003361 | 0.00778 |
202 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 13 | 167 | 0.0003447 | 0.007941 |
203 | DEVELOPMENTAL GROWTH | 20 | 333 | 0.0003524 | 0.008077 |
204 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 24 | 437 | 0.0003557 | 0.008113 |
205 | NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 7 | 53 | 0.0003627 | 0.008191 |
206 | MESONEPHRIC TUBULE MORPHOGENESIS | 7 | 53 | 0.0003627 | 0.008191 |
207 | REGULATION OF PROTEIN BINDING | 13 | 168 | 0.0003652 | 0.008209 |
208 | REGULATION OF GROWTH | 31 | 633 | 0.0003928 | 0.008787 |
209 | POSITIVE REGULATION OF GROWTH | 16 | 238 | 0.000399 | 0.008841 |
210 | HEMOSTASIS | 19 | 311 | 0.0003982 | 0.008841 |
211 | VENTRICULAR SEPTUM DEVELOPMENT | 7 | 54 | 0.0004077 | 0.00899 |
212 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 19 | 312 | 0.0004143 | 0.009092 |
213 | NEGATIVE REGULATION OF LOCOMOTION | 17 | 263 | 0.0004187 | 0.009147 |
214 | MUSCLE CELL DEVELOPMENT | 11 | 128 | 0.0004209 | 0.009152 |
215 | DEVELOPMENTAL MATURATION | 14 | 193 | 0.0004255 | 0.009208 |
216 | VENOUS BLOOD VESSEL DEVELOPMENT | 4 | 15 | 0.000446 | 0.009607 |
217 | REGULATION OF ANATOMICAL STRUCTURE SIZE | 25 | 472 | 0.0004617 | 0.009853 |
218 | ENDOTHELIUM DEVELOPMENT | 9 | 90 | 0.0004609 | 0.009853 |
219 | ENDOTHELIAL CELL DIFFERENTIATION | 8 | 72 | 0.0004656 | 0.009892 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ENZYME BINDING | 90 | 1737 | 4.065e-11 | 3.776e-08 |
2 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 27 | 328 | 8.958e-08 | 4.161e-05 |
3 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 37 | 629 | 2.034e-06 | 0.0006298 |
4 | MACROMOLECULAR COMPLEX BINDING | 64 | 1399 | 3.106e-06 | 0.0007213 |
5 | PROTEIN DOMAIN SPECIFIC BINDING | 36 | 624 | 4.341e-06 | 0.0008066 |
6 | CYTOSKELETAL PROTEIN BINDING | 43 | 819 | 5.66e-06 | 0.0008189 |
7 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 23 | 315 | 6.17e-06 | 0.0008189 |
8 | RECEPTOR BINDING | 65 | 1476 | 8.94e-06 | 0.001038 |
9 | KINASE ACTIVITY | 43 | 842 | 1.119e-05 | 0.001152 |
10 | TRANSCRIPTION FACTOR BINDING | 31 | 524 | 1.24e-05 | 0.001152 |
11 | KINASE BINDING | 34 | 606 | 1.441e-05 | 0.001217 |
12 | PROTEIN DIMERIZATION ACTIVITY | 53 | 1149 | 1.875e-05 | 0.001413 |
13 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 18 | 226 | 1.977e-05 | 0.001413 |
14 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 47 | 992 | 2.957e-05 | 0.001962 |
15 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 15 | 172 | 3.389e-05 | 0.002099 |
16 | PROTEIN HOMODIMERIZATION ACTIVITY | 37 | 722 | 4.319e-05 | 0.002508 |
17 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 53 | 1199 | 5.833e-05 | 0.003188 |
18 | PROTEIN COMPLEX BINDING | 44 | 935 | 6.261e-05 | 0.003231 |
19 | PROTEIN KINASE ACTIVITY | 33 | 640 | 9.962e-05 | 0.004871 |
20 | MOLECULAR FUNCTION REGULATOR | 57 | 1353 | 0.0001117 | 0.004979 |
21 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 92 | 0.0001125 | 0.004979 |
22 | BINDING BRIDGING | 14 | 173 | 0.0001374 | 0.005803 |
23 | ACTIN BINDING | 23 | 393 | 0.0001905 | 0.007373 |
24 | MAP KINASE KINASE KINASE ACTIVITY | 5 | 22 | 0.0001891 | 0.007373 |
25 | CALCIUM ION BINDING | 34 | 697 | 0.0002235 | 0.008305 |
26 | GLYCOPROTEIN BINDING | 10 | 101 | 0.0002449 | 0.00875 |
27 | REGULATORY REGION NUCLEIC ACID BINDING | 38 | 818 | 0.0002571 | 0.008846 |
28 | EPHRIN RECEPTOR BINDING | 5 | 24 | 0.0002927 | 0.009711 |
29 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 10 | 104 | 0.000311 | 0.009963 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE REGION | 59 | 1134 | 1.245e-07 | 7.273e-05 |
2 | MEMBRANE MICRODOMAIN | 23 | 288 | 1.367e-06 | 0.000399 |
3 | ACTIN CYTOSKELETON | 28 | 444 | 1.026e-05 | 0.00112 |
4 | CYTOSKELETON | 81 | 1967 | 7.915e-06 | 0.00112 |
5 | CELL SUBSTRATE JUNCTION | 26 | 398 | 1.15e-05 | 0.00112 |
6 | CELL LEADING EDGE | 24 | 350 | 1.123e-05 | 0.00112 |
7 | ANCHORING JUNCTION | 29 | 489 | 2.259e-05 | 0.001885 |
8 | PLASMA MEMBRANE REGION | 44 | 929 | 5.395e-05 | 0.003938 |
9 | PLASMA MEMBRANE RAFT | 10 | 86 | 6.327e-05 | 0.004106 |
10 | CELL JUNCTION | 51 | 1151 | 7.626e-05 | 0.004454 |
11 | PROTEIN KINASE COMPLEX | 10 | 90 | 9.341e-05 | 0.004959 |
12 | BASAL PLASMA MEMBRANE | 6 | 33 | 0.0001594 | 0.006371 |
13 | NEURON PROJECTION | 43 | 942 | 0.0001492 | 0.006371 |
14 | CELL PROJECTION | 70 | 1786 | 0.0001625 | 0.006371 |
15 | CELL PROJECTION PART | 43 | 946 | 0.0001636 | 0.006371 |
16 | NEURON PART | 53 | 1265 | 0.000225 | 0.008211 |
17 | BASAL PART OF CELL | 7 | 51 | 0.0002845 | 0.009774 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | PI3K_Akt_signaling_pathway_hsa04151 | 27 | 352 | 3.705e-07 | 1.4e-05 | |
2 | MAPK_signaling_pathway_hsa04010 | 24 | 295 | 5.778e-07 | 1.4e-05 | |
3 | Focal_adhesion_hsa04510 | 19 | 199 | 8.075e-07 | 1.4e-05 | |
4 | TNF_signaling_pathway_hsa04668 | 12 | 108 | 1.899e-05 | 0.0002468 | |
5 | Hippo_signaling_pathway_hsa04390 | 14 | 154 | 3.896e-05 | 0.0004052 | |
6 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 13 | 139 | 5.449e-05 | 0.0004305 | |
7 | Cellular_senescence_hsa04218 | 14 | 160 | 5.932e-05 | 0.0004305 | |
8 | Jak_STAT_signaling_pathway_hsa04630 | 14 | 162 | 6.792e-05 | 0.0004305 | |
9 | Hippo_signaling_pathway_multiple_species_hsa04392 | 6 | 29 | 7.45e-05 | 0.0004305 | |
10 | FoxO_signaling_pathway_hsa04068 | 12 | 132 | 0.0001374 | 0.0007144 | |
11 | Rap1_signaling_pathway_hsa04015 | 15 | 206 | 0.0002576 | 0.001218 | |
12 | HIF_1_signaling_pathway_hsa04066 | 9 | 100 | 0.000994 | 0.004308 | |
13 | TGF_beta_signaling_pathway_hsa04350 | 8 | 84 | 0.001302 | 0.00521 | |
14 | p53_signaling_pathway_hsa04115 | 7 | 68 | 0.001647 | 0.006117 | |
15 | Endocytosis_hsa04144 | 14 | 244 | 0.003923 | 0.0136 | |
16 | Sphingolipid_signaling_pathway_hsa04071 | 8 | 118 | 0.01041 | 0.03383 | |
17 | AMPK_signaling_pathway_hsa04152 | 8 | 121 | 0.012 | 0.0367 | |
18 | Ras_signaling_pathway_hsa04014 | 12 | 232 | 0.01566 | 0.04524 | |
19 | Ferroptosis_hsa04216 | 4 | 40 | 0.01815 | 0.04966 | |
20 | ErbB_signaling_pathway_hsa04012 | 6 | 85 | 0.02094 | 0.05444 | |
21 | Tight_junction_hsa04530 | 9 | 170 | 0.02961 | 0.07332 | |
22 | Phospholipase_D_signaling_pathway_hsa04072 | 8 | 146 | 0.03279 | 0.0775 | |
23 | Cell_cycle_hsa04110 | 7 | 124 | 0.03866 | 0.08294 | |
24 | Oocyte_meiosis_hsa04114 | 7 | 124 | 0.03866 | 0.08294 | |
25 | Regulation_of_actin_cytoskeleton_hsa04810 | 10 | 208 | 0.03987 | 0.08294 | |
26 | ECM_receptor_interaction_hsa04512 | 5 | 82 | 0.05725 | 0.1145 | |
27 | Apoptosis_hsa04210 | 7 | 138 | 0.06203 | 0.1195 | |
28 | Cytokine_cytokine_receptor_interaction_hsa04060 | 11 | 270 | 0.08375 | 0.1555 | |
29 | mTOR_signaling_pathway_hsa04150 | 7 | 151 | 0.09008 | 0.1615 | |
30 | Autophagy_animal_hsa04140 | 6 | 128 | 0.1073 | 0.1844 | |
31 | Adherens_junction_hsa04520 | 4 | 72 | 0.11 | 0.1844 | |
32 | Hedgehog_signaling_pathway_hsa04340 | 3 | 47 | 0.1162 | 0.1888 | |
33 | cGMP_PKG_signaling_pathway_hsa04022 | 7 | 163 | 0.1213 | 0.1912 | |
34 | Wnt_signaling_pathway_hsa04310 | 6 | 146 | 0.167 | 0.2554 | |
35 | Gap_junction_hsa04540 | 4 | 88 | 0.1844 | 0.2719 | |
36 | VEGF_signaling_pathway_hsa04370 | 3 | 59 | 0.1882 | 0.2719 | |
37 | Apoptosis_multiple_species_hsa04215 | 2 | 33 | 0.2036 | 0.2861 | |
38 | Mitophagy_animal_hsa04137 | 3 | 65 | 0.2277 | 0.3116 | |
39 | cAMP_signaling_pathway_hsa04024 | 6 | 198 | 0.3875 | 0.5166 | |
40 | NF_kappa_B_signaling_pathway_hsa04064 | 3 | 95 | 0.434 | 0.5643 | |
41 | Phosphatidylinositol_signaling_system_hsa04070 | 3 | 99 | 0.4606 | 0.5842 | |
42 | Cell_adhesion_molecules_.CAMs._hsa04514 | 4 | 145 | 0.5031 | 0.6229 | |
43 | Phagosome_hsa04145 | 4 | 152 | 0.5402 | 0.6533 | |
44 | Necroptosis_hsa04217 | 4 | 164 | 0.6003 | 0.7095 | |
45 | Peroxisome_hsa04146 | 2 | 83 | 0.6256 | 0.723 | |
46 | Calcium_signaling_pathway_hsa04020 | 4 | 182 | 0.6811 | 0.7699 | |
47 | Lysosome_hsa04142 | 2 | 123 | 0.8224 | 0.891 | |
48 | Apelin_signaling_pathway_hsa04371 | 2 | 137 | 0.8655 | 0.9185 | |
49 | Neuroactive_ligand_receptor_interaction_hsa04080 | 2 | 278 | 0.9937 | 1 |